The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic parenchymal injury, persistent activation of inflammatory response as well as sustained activation of liver fibrogenesis and wound healing response. Liver fibrogenesis, is a dynamic, highly integrated molecular, cellular and tissue process responsible for driving the excess accumulation of extracellular matrix (ECM) components (i.e., liver fibrosis) sustained by an eterogeneous population of hepatic myofibroblasts (MFs). The process of liver fibrogenesis recognizes a number of common and etiology-independent mechanisms and events but it is also significantly influenced by the specific etiology, as also reflected by peculiar morphological patterns of liver fibrosis development. In this review we will analyze the most relevant established and/or emerging pathophysiological issues underlying CLD progression with a focus on the role of critical hepatic cell populations, mechanisms and signaling pathways involved, as they represent potential therapeutic targets, to finally analyze selected and relevant clinical issues.
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, Maurizio
First
;
2019-01-01
Abstract
The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic parenchymal injury, persistent activation of inflammatory response as well as sustained activation of liver fibrogenesis and wound healing response. Liver fibrogenesis, is a dynamic, highly integrated molecular, cellular and tissue process responsible for driving the excess accumulation of extracellular matrix (ECM) components (i.e., liver fibrosis) sustained by an eterogeneous population of hepatic myofibroblasts (MFs). The process of liver fibrogenesis recognizes a number of common and etiology-independent mechanisms and events but it is also significantly influenced by the specific etiology, as also reflected by peculiar morphological patterns of liver fibrosis development. In this review we will analyze the most relevant established and/or emerging pathophysiological issues underlying CLD progression with a focus on the role of critical hepatic cell populations, mechanisms and signaling pathways involved, as they represent potential therapeutic targets, to finally analyze selected and relevant clinical issues.File | Dimensione | Formato | |
---|---|---|---|
Mol Aspects Med - post print.docx
Accesso riservato
Descrizione: Post print - versione finale dell'autore
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
279.03 kB
Formato
Adobe PDF
|
279.03 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Mol Asp Med 2018.pdf
Accesso riservato
Descrizione: File editoriale in press
Tipo di file:
PDF EDITORIALE
Dimensione
1.02 MB
Formato
Adobe PDF
|
1.02 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Mol Aspects Med - post print.pdf
Open Access dal 14/09/2019
Descrizione: Post print - versione finale dell'autore
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
574.63 kB
Formato
Adobe PDF
|
574.63 kB | Adobe PDF | Visualizza/Apri |
Parola_R1_Liver fibrosis.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.22 MB
Formato
Adobe PDF
|
1.22 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.